1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Analyzing the Global Pharmaceutical Industry 2015

Analyzing the Global Pharmaceutical Industry 2015

  • February 2015
  • -
  • Aruvian's R'search
  • -
  • 900 pages

The global presence of the pharmaceutical industry is evident with the roll out of continent specific R&D programs and drugs which help companies maximize penetration of markets and garner increased revenues with intercontinental treatment demand of patients being serviced from often one or two mega research centers in the continent.

By contribution of size, the pharmaceutical industry is majorly dominant at the US, Asia Pacific. Led by these markets, the total world consumption in sales of pharmaceutical products has displayed strong growth and is expected to grow further with expanding populations in emerging markets.

However, in recent times, austerity measures across the world along with many countires imposing cutbacks on healthcare spending (particularly in Europe), has hit the pharmaceutical industry. Furthermore, the loss of patent for many blockbuster drugs during the years 2010-2015 is also going to have a big impact on the global pharmaceutical industry. However, generic manufacturers are likely to benefit from this as they are poised to capture a substantial portion of revenues with their generic versions of these drugs.

Aruvian’s Research’s report – Analyzing the Global Pharmaceutical Industry - presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018.

The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy – store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat.

We analyze the global pharmaceutical industry, the global OTC market and the global generics industry through a Porter’s Five Forces Framework analysis.

We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry.

Industry structure is analyzed through a look at research and development pipelines, defense against generic competition, restructuring and outsourcing as well as the formation of strategic alliances. Analyzing the global pharmaceutical industry further, we take a look at the barriers to entry facing the industry, lifecycle of a drug, industry cost structure, industry trends and innovation, business environment and globalization of the global pharmaceutical industry.

Factors driving growth and change in the global pharmaceutical industry are analyzed. Analyzed factors include the emergence of new product lines, reasons for industry growth, opportunities in various CNS disorders and oncology research, ongoing commercialization of dormant compounds along with a look at the role of biosimilars in the industry. Moving on, we also analyzed the various challenges facing the global pharmaceutical industry and how the industry is dealing with them.

The TRIPS agreement has been a point of debate in the globally wherein the issues are equally contested for the developing as well as the developed countries and the options of flexibility which have inculcated in the report are explained in this report. Apart from this, another interesting phenomenon explained in this report is the practice of “offshoring” amongst the pharma companies and the value chains which have been developed to service them globally.

An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. A total of 27 markets analyzed in our report include:

• Australia
• Belgium
• Brazil
• Canada
• China
• Czech Republic
• Denmark
• France
• Germany
• Hungary
• India
• Italy
• Japan
• Mexico
• Netherlands
• New Zealand
• Norway
• Poland
• Russia
• Singapore
• South Africa
• South Korea
• Spain
• Sweden
• Taiwan
• United Kingdom
• United States

Moving on, a comprehensive analysis of the major industry players is undertaken. The players are analyzed through a corporate profile, an analysis of their major business segments, a financial analysis, ratio analysis, a look at their major products & services as well as a SWOT analysis. A total of 46 companies in our report.

With over 200 figures & tables, this highly insightful and analytical report from Aruvian Research is a complete & up-to-date coverage of the Global Pharmaceutical Industry.

Table Of Contents

Analyzing the Global Pharmaceutical Industry 2015
Executive Summary

Section 1: Analyzing the Global Pharmaceutical Industry

A. Historical Perspective of the Global Pharmaceutical Industry

B. Analysis of the Global Pharmaceutical Industry
B.1 Industry Definitions
B.1.1 Pharmaceutical Industry
B.1.2 Bulk Drugs
B.1.3 Formulations
B.2 Industry Statistics
B.3 Industry Value Analysis
B.4 Market Segments
B.5 Market Share Analysis
B.6 Competition in the Industry
B.7 Market Forecast

C. Global Pharmaceutical Industry: Porter's Five Forces Strategy Analysis
C.1 Introduction
C.2 Bargaining Power of Buyers
C.3 Bargaining Power of Suppliers
C.4 Competitive Rivalry in the Industry
C.5 Threat of New Entrants
C.6 Threat of Substitutes

D. Analysis of the Global OTC Pharmaceutical Industry
D.1 Industry Definition
D.2 Industry Statistics
D.3 Industry Value Analysis
D.4 Market Segments
D.5 Distribution Channels
D.6 Market Share Analysis
D.7 Market Forecast

E. Global OTC Pharmaceutical Industry: Porter's Five Forces Strategy Analysis
E.1 Introduction
E.2 Bargaining Power of Buyers
E.3 Bargaining Power of Suppliers
E.4 Competitive Rivalry in the Industry
E.5 Threat of New Entrants
E.6 Threat of Substitutes

F. Analysis the Global Generics Industry
F.1 Industry Definition
F.2 Industry Statistics
F.3 Industry Value and Volume Analysis
F.4 Market Segments
F.5 Industry Structure
F.6 Patent Expiries
F.7 Patent Expiries by Therapeutic Areas
F.8 Research and Development in the Industry
F.8.1 Super Generics
F.8.2 Biosimilars
F.9 Market Forecast

G. Global Generics Industry: Porter's Five Forces Strategy Analysis
G.1 Introduction
G.2 Bargaining Power of Buyers
G.3 Bargaining Power of Suppliers
G.4 Competitive Rivalry in the Industry
G.5 Threat of New Entrants
G.6 Threat of Substitutes

H. Structure of the Global Pharmaceutical Industry
H.1 RandD Pipelines
H.2 Defense against Generic Competition
H.3 Looking at Restructuring and Outsourcing
H.4 Strategic Alliances

I. Analyzing the Industry
I.1 Barriers to Entry
I.2 Lifecycle of a Drug
I.2.1 The Patent System
I.2.2 Drug Lifecycle
I.3 Industry Cost Structure
I.3.1 Types of Costs
I.3.2 Evidence on Cost Structure
I.3.3 Increasing Costs and Risks of Developing New Drugs
I.3.4 Conclusion
I.4 Trends in the Global Pharmaceutical Industry
I.5 Business Environment
I.6 Industry Innovation
I.7 Globalization of the Pharmaceutical Industry
I.8 Role of Genomics

J. Factors Driving Growth and Change in the Global Pharmaceutical Industry
J.1 Introduction
J.2 Growth in the Pharma Market
J.3 Reasons for Growth
J.4 New Product Lines
J.5 Opportunities in CNS Disorders and Oncology Research
J.6 Commercialization of Dormant Compounds
J.7 Generic/Biosimilar Versions of Biologics

K. Challenges Facing the Global Pharmaceutical Industry
K.1 Parallel Trade
K.2 Rising Cost of Healthcare
K.3 Immense Pressure on Industry Revenues
K.4 Uncertainty in Pipeline
K.5 Increasing Risks
K.6 Issues with Outcome-based Pricing

N. Offshoring in the Pharmaceutical Sector
N.1 Introduction
N.1.1 What is Offshoring?
N.1.2 Analyzing the Pharma Value Chain
N.1.3 Employment Scenario of the Pharmaceutical Industry
N.1.4 Why Offshore?
N.1.5 Primary Offshoring Locations
N.2 Offshoring of RandD
N.2.1 India
N.2.2 China
N.2.3 Growth Factors
N.2.4 Challenges and Barriers to Offshoring RandD
N.3 Offshoring of Pharmaceutical Manufacturing Processes
N.3.1 Overview
N.3.2 Biologics Manufacturing
N.3.3 API Manufacturing
N.3.4 Final Dosage Manufacturing
N.3.5 Growth Factors
N.3.6 Challenges and Barriers to Offshoring Manufacturing Processes

Section 2: Analyzing the Global Pharmaceutical Markets

A. Pharmaceutical Industry in Australia
A.1 Industry Statistics
A.2 Industry Value Analysis
A.3 Geographic Segmentation
A.4 Industry Trends
A.5 Production Trends
A.6 Market Share Analysis
A.7 Competition in the Industry
A.8 Industry Outlook

B. Pharmaceutical Industry in Belgium
B.1 Industry Statistics
B.2 Industry Value Analysis
B.3 Geographic Segmentation
B.4 Market Share Analysis
B.5 Competition in the Industry
B.6 Industry Outlook

C. Pharmaceutical Industry in Brazil
C.1 Industry Statistics
C.2 Industry Value Analysis
C.3 Geographic Segmentation
C.4 Market Share Analysis
C.5 Competition in the Industry
C.6 Industry Outlook

D. Pharmaceutical Industry in Canada
D.1 Industry Statistics
D.2 Industry Value Analysis
D.3 Geographic Segmentation
D.4 Market Share Analysis
D.5 Competition in the Industry
D.6 Industry Outlook

E. Pharmaceutical Industry in China
E.1 Industry Statistics
E.2 Industry Value Analysis
E.3 Geographic Segmentation
E.4 Industry Trends
E.5 Production Trends
E.6 Regulatory Framework
E.7 Market for Traditional Chinese Medicine
E.8 Market Share Analysis
E.9 Competition in the Industry
E.10 Industry Outlook

F. Pharmaceutical Industry in Czech Republic
F.1 Industry Statistics
F.2 Industry Value Analysis
F.3 Geographic Segmentation
F.4 Market Share Analysis
F.5 Competition in the Industry
F.6 Industry Outlook

G. Pharmaceutical Industry in Denmark
G.1 Industry Statistics
G.2 Industry Value Analysis
G.3 Geographic Segmentation
G.4 Market Share Analysis
G.5 Competition in the Industry
G.6 Industry Outlook

H. Pharmaceutical Industry in France
H.1 Industry Statistics
H.2 Industry Value Analysis
H.3 Geographic Segmentation
H.4 Market Share Analysis
H.5 Competition in the Industry
H.6 Industry Outlook

I. Pharmaceutical Industry in Germany
I.1 Industry Statistics
I.2 Industry Value Analysis
I.3 Geographic Segmentation
I.4 Market Share Analysis
I.5 Competition in the Industry
I.6 Industry Outlook

J. Pharmaceutical Industry in Hungary
J.1 Industry Statistics
J.2 Industry Value Analysis
J.3 Geographic Segmentation
J.4 Market Share Analysis
J.5 Competition in the Industry
J.6 Industry Outlook

K. Pharmaceutical Industry in India
K.1 Industry Statistics
K.2 Industry Value Analysis
K.3 Geographic Segmentation
K.4 Industry Trends
K.5 Production Trends
K.6 Market Share Analysis
K.7 Competition in the Industry
K.8 Industry Outlook

L. Pharmaceutical Industry in Italy
L.1 Industry Statistics
L.2 Industry Value Analysis
L.3 Geographic Segmentation
L.4 Market Share Analysis
L.5 Competition in the Industry
L.6 Industry Outlook

M. Pharmaceutical Industry in Japan
M.1 Industry Statistics
M.2 Industry Value Analysis
M.3 Geographic Segmentation
M.4 Industry Trends
M.5 Production Trends
M.6 Market Share Analysis
M.7 Competition in the Industry
M.8 Industry Outlook

N. Pharmaceutical Industry in Mexico
N.1 Industry Statistics
N.2 Industry Value Analysis
N.3 Geographic Segmentation
N.4 Market Share Analysis
N.5 Competition in the Industry
N.6 Industry Outlook

O. Pharmaceutical Industry in Netherlands
O.1 Industry Statistics
O.2 Industry Value Analysis
O.3 Geographic Segmentation
O.4 Market Share Analysis
O.5 Competition in the Industry
O.6 Industry Outlook

P. Pharmaceutical Industry in New Zealand
P.1 Industry Statistics
P.2 Industry Value Analysis
P.3 Geographic Segmentation
P.4 Market Share Analysis
P.5 Competition in the Industry
P.6 Industry Outlook

Q. Pharmaceutical Industry in Norway
Q.1 Industry Statistics
Q.2 Industry Value Analysis
Q.3 Geographic Segmentation
Q.4 Market Share Analysis
Q.5 Competition in the Industry
Q.6 Industry Outlook

R. Pharmaceutical Industry in Poland
R.1 Industry Statistics
R.2 Industry Value Analysis
R.3 Geographic Segmentation
R.4 Market Share Analysis
R.5 Competition in the Industry
R.6 Industry Outlook

S. Pharmaceutical Industry in Russia
S.1 Industry Statistics
S.2 Industry Value Analysis
S.3 Geographic Segmentation
S.4 Market Share Analysis
S.5 Competition in the Industry
S.6 Industry Outlook

T. Pharmaceutical Industry in Singapore
T.1 Industry Statistics
T.2 Industry Value Analysis
T.3 Geographic Segmentation
T.4 Market Share Analysis
T.5 Competition in the Industry
T.6 Industry Outlook

U. Pharmaceutical Industry in South Africa
U.1 Industry Statistics
U.2 Industry Value Analysis
U.3 Geographic Segmentation
U.4 Market Share Analysis
U.5 Competition in the Industry
U.6 Industry Outlook

V. Pharmaceutical Industry in South Korea
V.1 Industry Statistics
V.2 Industry Value Analysis
V.3 Geographic Segmentation
V.4 Market Share Analysis
V.5 Competition in the Industry
V.6 Industry Outlook

W. Pharmaceutical Industry in Spain
W.1 Industry Statistics
W.2 Industry Value Analysis
W.3 Geographic Segmentation
W.4 Market Share Analysis
W.5 Competition in the Industry
W.6 Industry Outlook

X. Pharmaceutical Industry in Sweden
X.1 Industry Statistics
X.2 Industry Value Analysis
X.3 Geographic Segmentation
X.4 Market Share Analysis
X.5 Competition in the Industry
X.6 Industry Outlook

Y. Pharmaceutical Industry in Taiwan
Y.1 Industry Statistics
Y.2 Industry Value Analysis
Y.3 Geographic Segmentation
Y.4 Market Share Analysis
Y.5 Competition in the Industry
Y.6 Industry Outlook

Z. Pharmaceutical Industry in United Kingdom
Z.1 Industry Statistics
Z.2 Industry Value Analysis
Z.3 Geographic Segmentation
Z.4 Market Share Analysis
Z.5 Competition in the Industry
Z.6 Industry Outlook

AA. Pharmaceutical Industry in the United States
AA.1 Industry Statistics
AA.2 Industry Value Analysis
AA.3 Geographic Segmentation
AA.4 Market Share Analysis
AA.5 Competition in the Industry
AA.6 Industry Outlook

Section 3: Analyzing the Major Market Players

A. Abbott Laboratories
A.1 Corporate Profile
A.2 Business Segment Analysis
A.3 Financial Analysis
A.4 Ratio Analysis
A.5 Major Products and Services
A.6 SWOT Analysis

B. Allergan, Inc.
B.1 Corporate Profile
B.2 Business Segment Analysis
B.3 Financial Analysis
B.4 Ratio Analysis
B.5 Major Products and Services
B.6 SWOT Analysis

C. Amgen, Inc.
C.1 Corporate Profile
C.2 Business Segment Analysis
C.3 Financial Analysis
C.4 Ratio Analysis
C.5 Major Products and Services
C.6 SWOT Analysis

D. Apotex, Inc.
D.1 Corporate Profile
D.2 Business Segment Analysis
D.3 Financial Analysis
D.4 Ratio Analysis
D.5 Major Products and Services
D.6 SWOT Analysis

E. Aspen Pharmacare Holdings Limited
E.1 Corporate Profile
E.2 Business Segment Analysis
E.3 Financial Analysis
E.4 Ratio Analysis
E.5 Major Products and Services
E.6 SWOT Analysis

F. Astellas Pharma
F.1 Corporate Profile
F.2 Business Segment Analysis
F.3 Financial Analysis
F.4 Ratio Analysis
F.5 Major Products and Services
F.6 SWOT Analysis

G. AstraZeneca
G.1 Corporate Profile
G.2 Business Segment Analysis
G.3 Financial Analysis
G.4 Ratio Analysis
G.5 Major Products and Services
G.6 SWOT Analysis

H. Baxter International
H.1 Corporate Profile
H.2 Business Segment Analysis
H.3 Financial Analysis
H.4 Ratio Analysis
H.5 Major Products and Services
H.6 SWOT Analysis

I. Bayer AG
I.1 Corporate Profile
I.2 Business Segment Analysis
I.3 Financial Analysis
I.4 Ratio Analysis
I.5 Major Products and Services
I.6 SWOT Analysis

J. Boehringer Ingelheim
J.1 Corporate Profile
J.2 Business Segment Analysis
J.3 Financial Analysis
J.4 Ratio Analysis
J.5 Major Products and Services
J.6 SWOT Analysis

K. Bristol-Myers Squibb
K.1 Corporate Profile
K.2 Business Segment Analysis
K.3 Financial Analysis
K.4 Ratio Analysis
K.5 Major Products and Services
K.6 SWOT Analysis

L. Chugai Pharmaceutical
L.1 Corporate Profile
L.2 Business Segment Analysis
L.3 Financial Analysis
L.4 Ratio Analysis
L.5 Major Products and Services
L.6 SWOT Analysis

M. Daewoong Pharmaceutical Co Ltd.
M.1 Corporate Profile
M.2 Business Segment Analysis
M.3 Financial Analysis
M.4 Ratio Analysis
M.5 Major Products and Services
M.6 SWOT Analysis

N. Daiichi Sankyo Company
N.1 Corporate Profile
N.2 Business Segment Analysis
N.3 Financial Analysis
N.4 Ratio Analysis
N.5 Major Products and Services
N.6 SWOT Analysis

O. Eisai Co., Ltd
O.1 Corporate Profile
O.2 Business Segment Analysis
O.3 Financial Analysis
O.4 Ratio Analysis
O.5 Major Products and Services
O.6 SWOT Analysis

P. Eli Lilly and Company
P.1 Corporate Profile
P.2 Business Segment Analysis
P.3 Financial Analysis
P.4 Ratio Analysis
P.5 Major Products and Services
P.6 SWOT Analysis

Q. F. Hoffmann-La Roche
Q.1 Corporate Profile
Q.2 Business Segment Analysis
Q.3 Financial Analysis
Q.4 Ratio Analysis
Q.5 Major Products and Services
Q.6 SWOT Analysis

R. GlaxoSmithKline Plc
R.1 Corporate Profile
R.2 Business Segment Analysis
R.3 Financial Analysis
R.4 Ratio Analysis
R.5 Major Products and Services
R.6 SWOT Analysis

S. Johnson and Johnson
S.1 Corporate Profile
S.2 Business Segment Analysis
S.3 Financial Analysis
S.4 Ratio Analysis
S.5 Major Products and Services
S.6 SWOT Analysis

T. Lupin Limited
T.1 Corporate Profile
T.2 Business Segment Analysis
T.3 Financial Analysis
T.4 Ratio Analysis
T.5 Major Products and Services
T.6 SWOT Analysis

U. Merck and Co.
U.1 Corporate Profile
U.2 Business Segment Analysis
U.3 Financial Analysis
U.4 Ratio Analysis
U.5 Major Products and Services
U.6 SWOT Analysis

V. Novartis AG
V.1 Corporate Profile
V.2 Business Segment Analysis
V.3 Financial Analysis
V.4 Ratio Analysis
V.5 Major Products and Services
V.6 SWOT Analysis

W. Pfizer
W.1 Corporate Profile
W.2 Business Segment Analysis
W.3 Financial Analysis
W.4 Ratio Analysis
W.5 Major Products and Services
W.6 SWOT Analysis

X. Richter Gedeon Vegyeszeti Gyar Nyrt
X.1 Corporate Profile
X.2 Business Segment Analysis
X.3 Financial Analysis
X.4 Ratio Analysis
X.5 Major Products and Services
X.6 SWOT Analysis

Y. Sanofi SA
Y.1 Corporate Profile
Y.2 Business Segment Analysis
Y.3 Financial Analysis
Y.4 Ratio Analysis
Y.5 Major Products and Services
Y.6 SWOT Analysis

Z. Shanghai Pharmaceuticals Holding Co. Ltd.
Z.1 Corporate Profile
Z.2 Business Segment Analysis
Z.3 Financial Analysis
Z.4 Ratio Analysis
Z.5 Major Products and Services
Z.6 SWOT Analysis

AA. Sumitomo Dainippon Pharma
AA.1 Corporate Profile
AA.2 Business Segment Analysis
AA.3 Financial Analysis
AA.4 Ratio Analysis
AA.5 Major Products and Services
AA.6 SWOT Analysis

BB. Takeda Pharmaceutical Company Limited
BB.1 Corporate Profile
BB.2 Business Segment Analysis
BB.3 Financial Analysis
BB.4 Ratio Analysis
BB.5 Major Products and Services
BB.6 SWOT Analysis

CC. Teva Pharmaceutical Industries
CC.1 Corporate Profile
CC.2 Business Segment Analysis
CC.3 Financial Analysis
CC.4 Ratio Analysis
CC.5 Major Products and Services
CC.6 SWOT Analysis

DD. Aurobindo Pharma Ltd
DD.1 Corporate Profile
DD.2 Business Segment Analysis
DD.3 Financial Analysis
DD.4 Ratio Analysis
DD.5 Major Products and Services

EE. Cadila Healthcare
EE.1 Corporate Profile
EE.2 Business Segment Analysis
EE.3 Financial Analysis
EE.4 Ratio Analysis
EE.5 Major Products and Services

FF. China National Accord Medicines Corporation Ltd
FF.1 Corporate Profile
FF.2 Business Segment Analysis
FF.3 Financial Analysis
FF.4 Ratio Analysis
FF.5 Major Products and Services

GG. Cipla Ltd
GG.1 Corporate Profile
GG.2 Business Segment Analysis
GG.3 Financial Analysis
GG.4 Ratio Analysis
GG.5 Major Products and Services

HH. Dr. Reddy's Laboratories Limited
HH.1 Corporate Profile
HH.2 Business Segment Analysis
HH.3 Financial Analysis
HH.4 Ratio Analysis
HH.5 Major Products and Services

II. Hanmi Science Co Ltd
II.1 Corporate Profile
II.2 Business Segment Analysis
II.3 Financial Analysis
II.4 Ratio Analysis
II.5 Major Products and Services

JJ. Harbin Pharmaceutical Group Co. Ltd.
JJ.1 Corporate Profile
JJ.2 Business Segment Analysis
JJ.3 Financial Analysis
JJ.4 Ratio Analysis
JJ.5 Major Products and Services

KK. Jubilant Life Sciences Ltd
KK.1 Corporate Profile
KK.2 Business Segment Analysis
KK.3 Financial Analysis
KK.4 Ratio Analysis
KK.5 Major Products and Services

LL. Mylan Laboratories Ltd
LL.1 Corporate Profile
LL.2 Business Segment Analysis
LL.3 Financial Analysis
LL.4 Ratio Analysis
LL.5 Major Products and Services

MM. Pharmstandard OJSC
MM.1 Corporate Profile
MM.2 Business Segment Analysis
MM.3 Financial Analysis
MM.4 Ratio Analysis
MM.5 Major Products and Services

NN. Ranbaxy Laboratories
NN.1 Corporate Profile
NN.2 Business Segment Analysis
NN.3 Financial Analysis
NN.4 Ratio Analysis
NN.5 Major Products and Services

OO. Sun Pharmaceutical Industries
OO.1 Corporate Profile
OO.2 Business Segment Analysis
OO.3 Financial Analysis
OO.4 Ratio Analysis
OO.5 Major Products and Services

PP. Taisho Pharmaceutical Co., Ltd.
PP.1 Corporate Profile
PP.2 Business Segment Analysis
PP.3 Financial Analysis
PP.4 Ratio Analysis
PP.5 Major Products and Services

QQ. Chiesi Farmaceutici SpA

RR. Dong-A Pharmaceutical Co. Ltd

SS. Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.

TT. Yunnan Baiyao Group

Section 4: Glossary of Terms


List of Figures

Figure 1: Value of the Global Pharmaceutical Industry (in USD Billion), 2009-2013
Figure 2: Segmentation of the Global Pharmaceutical Industry by Regions (%), 2013
Figure 3: Market Share of the Global Pharmaceutical Industry (%), 2013
Figure 4: Forecast of the Global Pharmaceutical Industry (in USD Billion), 2013-2018
Figure 5: Porter's Five Forces Analysis of the Global Pharmaceutical Industry
Figure 6: Buyer Power in the Global Pharmaceutical Industry
Figure 7: Supplier Power in the Global Pharmaceutical Industry
Figure 8: Rivalry in the Global Pharmaceutical Industry
Figure 9: Threat of New Entrants in the Global Pharmaceutical Industry
Figure 10: Threat of Substitutes in the Global Pharmaceutical Industry
Figure 11: Value of the Global OTC Pharmaceutical Industry (in USD Million), 2009-2013
Figure 12: Segmentation of the Global OTC Pharmaceutical Market by Categories (%), 2013
Figure 13: Segmentation of the Global OTC Pharmaceutical Market by Regions (%), 2013
Figure 14: Major Distribution Channels in the Global OTC Pharma Market (%), 2013
Figure 15: Market Share of the Global Pharmaceutical Industry (%), 2013
Figure 16: Forecast of the Global OTC Pharmaceutical Industry (in USD Million), 2013-2018
Figure 17: Porter's Five Forces Analysis of the Global OTC Pharmaceutical Industry
Figure 18: Buyer Power in the Global OTC Pharmaceutical Industry
Figure 19: Supplier Power in the Global OTC Pharmaceutical Industry
Figure 20: Competition in the Global OTC Pharmaceutical Industry
Figure 21: Threat of New Entrants in the Global OTC Pharmaceutical Industry
Figure 22: Threat of Substitutes in the Global OTC Pharmaceutical Industry
Figure 23: Historical Revenues of Leading Generic Companies (in USD Million), 2008-2009
Figure 24: Generics Percentage of Total Pharmaceutical Volume and Market Volume of Global Generics Industry (%), 2009-2013
Figure 25: Global Generics Market Segmentation by Geography (%), 2013
Figure 26: Market Share of Leading Generic Companies Worldwide (%), 2013
Figure 27: Comparison of Revenues of Leading Generic Companies (in USD Million), 2011-2012
Figure 28: Revenues of Top 10 Drugs Facing Patent Expiries between 2010-2014 (in USD Million)
Figure 29: Value of Drugs to Lose Patent Protection during 2010-2014 by Therapeutic Area (%)
Figure 30: Global Generics Industry Forecast (in USD Million), 2013-2018
Figure 31: Global Generics Industry Forecast by Volume (%), 2013-2018
Figure 32: Porter's Five Forces Analysis of the Global Generics Industry
Figure 33: Buyer Power in the Global Generics Industry
Figure 34: Supplier Power in the Global Generics Industry
Figure 35: Competition in the Global Generics Industry
Figure 36: Threat of New Entrants in the Global Generics Industry
Figure 37: Threat of Substitutes in the Global Generics Industry
Figure 38: Lifecycle of a Drug: from Patent to Patient
Figure 39: Trends in RandD to Sales Ratio, 1970-2000
Figure 40: Factors Impacting the Growth of the Pharma Industry
Figure 41: Factors Restraining the Pharma Market
Figure 42: Healthcare Expenditure as a Percentage of GDP in the US, 1960-2010
Figure 43: Number of Compounds to Produce a New Drug
Figure 44: Expense of Clinical Trials in Emerging Markets
Figure 45: Offshoring Business Models
Figure 46: Pharmaceutical Value Chain
Figure 47: Global Pharmaceutical Employment by Region (%), 2013
Figure 48: Global Pharmaceutical Employment by Segment (%), 2013
Figure 49: MPCs' RandD Activities in India
Figure 50: India's Pharmaceutical RandD Environment
Figure 51: China's Pharmaceutical RandD Environment
Figure 52: Comparing Pharmaceutical RandD Capabilities between China and India
Figure 53: Advantages of Conducting Clinical Trials in China and India
Figure 54: Comparing Costs of Formulation Manufacturing between USA and India
Figure 55: Breakdown of Formulation Manufacturing Cost Advantage in India
Figure 56: Value of the Pharmaceutical Industry in Australia (in USD Billion), 2009-2013
Figure 57: Share of Australia in the Asia Pacific Pharmaceutical Industry (%), 2013
Figure 58: Market Share of the Australian Pharmaceutical Industry (%), 2013
Figure 59: Forecast of the Pharmaceutical Industry in Australia (in USD Billion), 2013-2018
Figure 60: Value of the Pharmaceutical Industry in Belgium (in USD Billion), 2009-2013
Figure 61: Share of Belgium in the European Pharmaceutical Industry (%), 2013
Figure 62: Market Share of the Belgian Pharmaceutical Industry (%), 2013
Figure 63: Forecast of the Pharmaceutical Industry in Belgium (in USD Billion), 2013-2018
Figure 64: Value of the Pharmaceutical Industry in Brazil (in USD Billion), 2009-2013
Figure 65: Share of Brazil in the Americas Pharmaceutical Industry (%), 2013
Figure 66: Market Share of the Global Pharmaceutical Industry (%), 2013
Figure 67: Forecast of the Pharmaceutical Industry in Brazil (in USD Billion), 2013-2018
Figure 68: Value of the Pharmaceutical Industry in Canada (in USD Billion), 2009-2013
Figure 69: Share of Canada in the Americas Pharmaceutical Industry (%), 2013
Figure 70: Market Share of the Canadian Pharmaceutical Industry (%), 2013
Figure 71: Forecast of the Pharmaceutical Industry in Canada (in USD Billion), 2013-2018
Figure 72: Total Asset of Pharmaceutical Industry in China, 2004-2013
Figure 73: Revenue and Net Profit Margin of Pharmaceutical Industry in China, 2006-2013
Figure 74: China's Pharmaceutical Industry Revenue by Product Category (%), 2013
Figure 75: Pharmaceutical Market by Therapeutic Area (%), 2013
Figure 76: Value of the Pharmaceutical Industry in China (in USD Billion), 2009-2013
Figure 77: Share of China in the Asia Pacific Pharmaceutical Industry (%), 2013
Figure 78: Revenue of Traditional Chinese Medicine (in RMB Billion), 2002-2013
Figure 79: Market Share of the Chinese Pharmaceutical Industry (%), 2013
Figure 80: Forecast of the Pharmaceutical Industry in China (in USD Billion), 2013-2018
Figure 81: Value of the Pharmaceutical Industry in Czech Republic (in USD Billion), 2009-2013
Figure 82: Share of Czech Republic in the European Pharmaceutical Industry (%), 2013
Figure 83: Market Share of the Czech Republic Pharmaceutical Industry (%), 2013
Figure 84: Forecast of the Czech Republic Pharmaceutical Industry (in USD Billion), 2013-2018
Figure 85: Value of the Pharmaceutical Industry in Denmark (in USD Billion), 2009-2013
Figure 86: Share of Denmark in the European Pharmaceutical Industry (%), 2013
Figure 87: Market Share of the Danish Pharmaceutical Industry (%), 2013
Figure 88: Forecast of the Pharmaceutical Industry in Denmark (in USD Billion), 2013-2018
Figure 89: Value of the Pharmaceutical Industry in France (in USD Billion), 2009-2013
Figure 90: Share of France in the European Pharmaceutical Industry (%), 2013
Figure 91: Market Share of the French Pharmaceutical Industry (%), 2013
Figure 92: Forecast of the Pharmaceutical Industry in France (in USD Billion), 2013-2018
Figure 93: Value of the Pharmaceutical Industry in Germany (in USD Billion), 2009-2013
Figure 94: Share of Germany in the European Pharmaceutical Industry (%), 2013
Figure 95: Market Share Analysis of the German Pharmaceutical Industry (%), 2013
Figure 96: Forecast of the Pharmaceutical Industry in Germany (in USD Billion), 2013-2018
Figure 97: Value of the Pharmaceutical Industry in Hungary (in USD Billion), 2009-2013
Figure 98: Share of Hungary in the European Pharmaceutical Industry (%), 2013
Figure 99: Market Share of the Hungarian Pharmaceutical Industry (%), 2013
Figure 100: Forecast of the Pharmaceutical Industry in Hungary (in USD Billion), 2013-2018
Figure 101: Value of the Pharmaceutical Industry in India (in USD Billion), 2009-2013
Figure 102: Share of India in the Asia Pacific Pharmaceutical Industry (%), 2013
Figure 103: Market Share of the Indian Pharmaceutical Industry (%), 2013
Figure 104: Forecast of the Pharmaceutical Industry in India (in USD Billion), 2013-2018
Figure 105: Value of the Pharmaceutical Industry in Italy (in USD Billion), 2009-2013
Figure 106: Share of Italy in the European Pharmaceutical Industry (%), 2013
Figure 107: Market Share of the Italian Pharmaceutical Industry (%), 2013
Figure 108: Forecast of the Pharmaceutical Industry in Italy (in USD Billion), 2013-2018
Figure 109: Value of the Pharmaceutical Industry in Japan (in USD Billion), 2009-2013
Figure 110: Share of Japan in the Asia Pacific Pharmaceutical Industry (%), 2013
Figure 111: Market Share of the Japanese Pharmaceutical Industry (%), 2013
Figure 112: Forecast of the Pharmaceutical Industry in Japan (in USD Billion), 2013-2018
Figure 113: Value of the Pharmaceutical Industry in Mexico (in USD Billion), 2009-2013
Figure 114: Share of Mexico in the Americas Pharmaceutical Industry (%), 2013
Figure 115: Market Share of the Mexican Pharmaceutical Industry (%), 2013
Figure 116: Forecast of the Pharmaceutical Industry in Mexico (in USD Billion), 2013-2018
Figure 117: Value of the Dutch Pharmaceutical Industry (in USD Billion), 2009-2013
Figure 118: Share of Netherlands in the European Pharmaceutical Industry (%), 2013
Figure 119: Market Share of the Netherlands Pharmaceutical Industry (%), 2013
Figure 120: Forecast of the Netherlands Pharmaceutical Industry (in USD Billion), 2013-2018
Figure 121: Value of the New Zealand Pharmaceutical Industry (in USD Billion), 2009-2013
Figure 122: Share of New Zealand in the Asia Pacific Pharmaceutical Industry (%), 2013
Figure 123: Market Share of the New Zealand Pharmaceutical Industry (%), 2013
Figure 124: Forecast of the New Zealand Pharmaceutical Industry (in USD Billion), 2013-2018
Figure 125: Value of the Pharmaceutical Industry in Norway (in USD Billion), 2009-2013
Figure 126: Share of Norway in the European Pharmaceutical Industry (%), 2013
Figure 127: Market Share of the Norwegian Pharmaceutical Industry (%), 2013
Figure 128: Value of the Pharmaceutical Industry in Norway (in USD Billion), 2009-2013
Figure 129: Value of the Pharmaceutical Industry in Poland (in USD Billion), 2009-2013
Figure 130: Share of Poland in the European Pharmaceutical Industry (%), 2013
Figure 131: Market Share of the Polish Pharmaceutical Industry (%), 2013
Figure 132: Forecast of the Pharmaceutical Industry in Poland (in USD Billion), 2013-2018
Figure 133: Value of the Pharmaceutical Industry in Russia (in USD Billion), 2009-2013
Figure 134: Share of Russia in the European Pharmaceutical Industry (%), 2013
Figure 135: Market Share of the Russian Pharmaceutical Industry (%), 2013
Figure 136: Forecast of the Pharmaceutical Industry in Russia (in USD Billion), 2013-2018
Figure 137: Value of the Pharmaceutical Industry in Singapore (in USD Billion), 2009-2013
Figure 138: Share of Singapore in the Asia Pacific Pharmaceutical Industry (%), 2013
Figure 139: Market Share of the Singaporean Pharmaceutical Industry (%), 2013
Figure 140: Forecast of the Pharmaceutical Industry in Singapore (in USD Billion), 2013-2018
Figure 141: Value of the Pharmaceutical Industry in South Africa (in USD Billion), 2009-2013
Figure 142: Share of South Africa in the MEA Pharmaceutical Industry (%), 2013
Figure 143: Market Share of the South African Pharmaceutical Industry (%), 2013
Figure 144: Forecast of the Pharmaceutical Industry in South Africa (in USD Billion), 2013-2018
Figure 145: Value of the Pharmaceutical Industry in South Korea (in USD Billion), 2009-2013
Figure 146: Share of South Korea in the Asia Pacific Pharmaceutical Industry (%), 2013
Figure 147: Market Share of the South Korean Pharmaceutical Industry (%), 2013
Figure 148: Forecast of the Pharmaceutical Industry in South Korea (in USD Billion), 2013-2018
Figure 149: Value of the Pharmaceutical Industry in Spain (in USD Billion), 2009-2013
Figure 150: Share of Spain in the European Pharmaceutical Industry (%), 2013
Figure 151: Market Share of the Spanish Pharmaceutical Industry (%), 2013
Figure 152: Forecast of the Pharmaceutical Industry in Spain (in USD Billion), 2013-2018
Figure 153: Value of the Pharmaceutical Industry in Sweden (in USD Billion), 2009-2013
Figure 154: Share of Sweden in the European Pharmaceutical Industry (%), 2013
Figure 155: Market Share of the Swedish Pharmaceutical Industry (%), 2013
Figure 156: Forecast of the Pharmaceutical Industry in Sweden (in USD Billion), 2013-2018
Figure 157: Value of the Pharmaceutical Industry in Taiwan (in USD Billion), 2009-2013
Figure 158: Share of Taiwan in the Asia Pacific Pharmaceutical Industry (%), 2013
Figure 159: Market Share of the Taiwanese Pharmaceutical Industry (%), 2013
Figure 160: Forecast of the Pharmaceutical Industry in Taiwan (in USD Billion), 2013-2018
Figure 161: Value of the Pharmaceutical Industry in UK (in USD Billion), 2009-2013
Figure 162: Share of UK in the European Pharmaceutical Industry (%), 2013
Figure 163: Market Share of the UK Pharmaceutical Industry (%), 2013
Figure 164: Forecast of the UK Pharmaceutical Industry (in USD Billion), 2013-2018
Figure 165: Value of the US Pharmaceutical Industry (in USD Billion), 2009-2013
Figure 166: Share of United States in the Global Pharmaceutical Industry (%), 2013
Figure 167: Market Share of the US Pharmaceutical Industry (%), 2013
Figure 168: Forecast of the US Pharmaceutical Industry (in USD Billion), 2013-2018
Figure 169: Financial Performance of Abbott Laboratories (in USD Million), 2009-2013
Figure 170: Financial Performance of Allergan, Inc. (in USD Million), 2009-2013
Figure 171: Financial Performance of Amgen Inc. (in USD Million), 2009-2013
Figure 172: Financial Performance of Aspen Pharmacare (in ZAR Million), 2010-2014
Figure 173: Financial Performance of Astellas Pharma (in JPY Million), 2010-2014
Figure 174: Financial Performance of AstraZeneca Plc (in USD Million), 2009-2013
Figure 175: Financial Performance of Baxter International (in USD Million), 2009-2013
Figure 176: Financial Performance of Bayer AG (in USD Million), 2009-2013
Figure 177: Financial Performance of Bristol-Myers Squibb (in USD Million), 2009-2013
Figure 178: Financial Performance of Chugai Pharmaceutical (in JPY Million), 2009-2013
Figure 179: Financial Performance of Daewoong Pharmaceutical (in KRW Million), 2009-2013
Figure 180: Financial Performance of Daiichi Sankyo Company (in JPY Million), 2010-2014
Figure 181: Financial Performance of Eisai Co. (in JPY Million), 2010-2014
Figure 182: Financial Performance of Eli Lilly and Company (in USD Million), 2009-2013
Figure 183: Financial Performance of F. Hoffmann-La Roche (in CHF Million), 2009-2013
Figure 184: Financial Performance of GlaxoSmithKline (in GBP Million), 2009-2013
Figure 185: Financial Performance of Johnson and Johnson (in USD Million), 2009-2013
Figure 186: Financial Performance of Lupin (in INR Million), 2010-2014
Figure 187: Financial Performance of Merck and Co. (in USD Million), 2009-2013
Figure 188: Financial Performance of Novartis AG (in USD Million), 2009-2013
Figure 189: Financial Performance of Pfizer (in USD Million), 2009-2013
Figure 190: Financial Performance of Richter Gedeon Vegyeszeti Gyar Nyrt (in HUF Million), 2009-2013
Figure 191: Financial Performance of Sanofi SA (in EUR Million), 2009-2013
Figure 192: Financial Performance of Shanghai Pharmaceuticals (in CNY Million), 2009-2013
Figure 193: Financial Performance of Sumitomo Dainippon Pharma (in JPY Million), 2010-2014
Figure 194: Financial Performance of Takeda Pharmaceutical Company (in USD Million), 2010-2014
Figure 195: Financial Performance of Teva Pharmaceutical Industries (in USD Million), 2009-2013
Figure 196: Financial Performance of Aurobindo Pharma (in INR Million), 2010-2014
Figure 197: Financial Performance of Cadila Healthcare (in INR Million), 2010-2014
Figure 198: Financial Performance of China National Accord Medicines Corporation (in USD Million), 2008-2012
Figure 199: Financial Performance of Cipla Ltd. (in INR Million), 2009-2013
Figure 200: Financial Performance of Dr. Reddy's Laboratories (in INR Million), 2010-2014
Figure 201: Financial Performance of Harbin Pharmaceutical Group (in CNY Million), 2009-2013
Figure 202: Financial Performance of Jubilant Life Sciences (in INR Million), 2010-2014
Figure 203: Financial Performance of Sun Pharmaceutical Industries (in INR Million), 2010-2014


List of Tables

Table 1: Value of the Global Pharmaceutical Industry (in USD Billion), 2009-2013
Table 2: Segmentation of the Global Pharmaceutical Industry by Regions (in USD Billion and %), 2013
Table 3: Forecast of the

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.